Therapy News and Research

RSS

Proton therapy preserves urinary and bowel function in men with prostate cancer

Two studies led by The University of Texas MD Anderson Cancer Center have found that proton therapy preserves the quality of life, specifically urinary and bowel function, in men treated with this targeted radiation modality for prostate cancer.

30 Oct 2012

Research dispels myth that sudden cardiac death happens mainly during sports

It's a tragic news story that often makes headlines - a young, healthy, fit athlete suddenly collapses and dies of cardiac arrest while playing sports.

30 Oct 2012

CINJ visiting scientist receives International - U.S. Annual Meeting Scientific Abstract Award

Songbing Qin, MD, a visiting scientist to The Cancer Institute of New Jersey, has received the International - U.S. Annual Meeting Scientific Abstract Award at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held in Boston this week.

30 Oct 2012

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery compared with surgery alone, researchers at the University of Maryland School of Medicine have found.

30 Oct 2012

IPSCs may be a viable source of patient-specific articular cartilage tissue

A team of Duke Medicine researchers has engineered cartilage from induced pluripotent stem cells that were successfully grown and sorted for use in tissue repair and studies into cartilage injury and osteoarthritis.

30 Oct 2012

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Language barriers and the immigration status of caregivers appear to impact the care of Hispanic children with cancer and affect the experience of the families within the medical system, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Complementary and alternative therapy offers self-reported benefits for arthritis patients

Nearly a quarter of patients with rheumatoid arthritis and osteoarthritis used complementary and alternative therapy (CAT) to help manage their condition, according to a study in the November issue of the Journal of Clinical Nursing.

30 Oct 2012

Notable Medicare lawsuit settlement could aid patients needing skilled nursing care, other types of therapy

News outlets explain how a recent Medicare settlement could have an important impact on people who need physical, occupational and other therapies for certain disabilities and chronic conditions.

30 Oct 2012

BioRx added to Zemaira distribution network

BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema.

30 Oct 2012

New hope for mitochondrial disease sufferers

Scientists have succeeded in replacing mitochondrial DNA in human oocytes, which they hope will lead to the procedure being developed for use in patients with mitochondrial diseases.

29 Oct 2012

Aspirin improves colorectal cancer survival in tandem with gene mutation

Aspirin significantly improves survival in colorectal cancer patients who have a mutation in a carcinogenesis-associated signaling pathway, the results of a US and Japanese study indicate.

29 Oct 2012

Carotid ultrasound improves risk management in rheumatoid arthritis

A trial of radiofrequency ultrasound in patients with rheumatoid arthritis has shown that carotid intima-media thickness is significantly greater in patients treated only with synthetic therapeutics compared with those who are also taking biologics.

29 Oct 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Antidepressant doxepin eases pain associated with oral mucositis

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

29 Oct 2012

New prostate cancer therapy triggers questions about cost, effectiveness and safety

Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.

29 Oct 2012

Botanical treatment holds hope for triple-negative breast cancer

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects.

29 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

Therapy News and Research

Proton therapy preserves urinary and bowel function in men with prostate cancer

Research dispels myth that sudden cardiac death happens mainly during sports

CINJ visiting scientist receives International - U.S. Annual Meeting Scientific Abstract Award

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery

IPSCs may be a viable source of patient-specific articular cartilage tissue

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

Complementary and alternative therapy offers self-reported benefits for arthritis patients

Notable Medicare lawsuit settlement could aid patients needing skilled nursing care, other types of therapy

BioRx added to Zemaira distribution network

New hope for mitochondrial disease sufferers

Aspirin improves colorectal cancer survival in tandem with gene mutation

Carotid ultrasound improves risk management in rheumatoid arthritis

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

Antidepressant doxepin eases pain associated with oral mucositis

New prostate cancer therapy triggers questions about cost, effectiveness and safety

Botanical treatment holds hope for triple-negative breast cancer

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News